Neurotech International (ASX:NTI) is a biopharmaceutical company focused on the development and commercialisation of neurological solutions that improve quality of life. The company's lead drug candidate, NTI164, is currently in Phase II clinical trials for the treatment of moderate autism spectrum disorder in children. NTI is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. NTI's operations are centred around its two key projects: the NTI164 clinical trials and the commercialisation of Mente.